



NEWS RELEASE

LEADERS FREE Patient Population Data Presented at EuroPCR: Enrollment Now Complete

Paris, France, 21 May 2014 – Biosensors International Group, Ltd. (“**Biosensors**” or the “**Company**”, Bloomberg: BIG SP; Reuters: BIOS.SI; SGX: B20), a developer, manufacturer and marketer of innovative medical devices, announced today the completion of enrollment for its LEADERS FREE study. The baseline patient population data from the LEADERS FREE study was also presented for the first time today at EuroPCR 2014 by Principal Investigator Dr. Philip Urban.

LEADERS FREE is the world’s first prospective, randomised double-blind trial employing only a one-month course of dual anti-platelet therapy (DAPT) after implantation of an active stent. The study is focused on patients at high risk of bleeding, and has been designed to confirm that BioFreedom™, Biosensors’ novel polymer and carrier-free drug-coated stent (DCS), is as safe as a bare-metal stent (BMS) in this patient group, while delivering the anti-restenotic benefit of a drug-eluting stent (DES).

The baseline data confirmed that patients considered by enrolling doctors to be at high bleed risk are significantly older and have more co-morbidities than the ‘all comers’ patient population routinely seen in clinical studies of cardiac stents. LEADERS FREE reported a mean average patient age of 76, more than a decade older than the norm. Analysis also revealed more patients than normal with additional conditions to coronary heart disease, predominantly cancer, peripheral vascular disease, prior stroke and renal failure.

“The results of this study will be particularly important as we hope that they will show, for the first time, that a drug-coated stent can be more effective than a bare metal stent, yet just as safe, in a subgroup of patients not previously studied”, Dr. Urban commented. “This study could potentially change clinical practice by permitting the use of a DCS in conjunction with only one month of DAPT”.

BioFreedom represents the latest development in Biosensors’ stent technology, featuring a micro-structured abluminal surface that permits the controlled release of Biolimus A9™ (BA9™) without the use of a polymer or other carrier. BA9 is a highly lipophilic anti-restenotic drug developed by Biosensors specifically for use with stents. In its First in Man (“FIM”) study, treatment with BioFreedom demonstrated excellent 12-month late lumen loss and sustained safety up to four years, including absence of definite and/or probable stent thrombosis.

LEADERS FREE has enrolled 2466 patients identified as having a high risk of bleeding from 68 sites across Europe, Asia, Australia and Canada. The trial plans to conduct two years of follow-up. Patients in both arms of the study are being prescribed only one month of DAPT.

The co-primary endpoints of the study are: 1) non-inferiority of BioFreedom compared with a BMS after one year as measured by specific safety factors (cardiac death, myocardial infarction, and definite/probable stent thrombosis) and; 2) superiority over BMS in terms of clinically-driven TLR after one year.

Primary endpoint data is expected in late 2015.

BioFreedom received CE Mark approval in January 2013 and is currently available in select markets. Earlier this month the Company also announced that it had received conditional IDE approval to conduct a U.S.-based clinical trial of BioFreedom, designed to collect additional safety and effectiveness data for the BioFreedom system and to support a future pivotal IDE study.

###

Media/Investor Relations Contact

Wong Teck Yenn
Director, Investor Relations
Tel: (65) 6213 5777
Email: ir@biosensors.com

About Biosensors International Group, Ltd

Biosensors International Group, Ltd. develops, manufactures and markets innovative medical devices, aiming to improve patients' lives through pioneering medical technology that pushes forward the boundaries of innovation. Founded in 1990, we were listed on the Mainboard of the Singapore Stock Exchange in 2005.

The Group currently operates through four business units ("BU"): the Cardiovascular BU, composed primarily of the BioMatrix™ family of drug-eluting stents and stent technologies such as BA9; the Cardiac Diagnostic BU, including Spectrum Dynamics products that offer advanced medical imaging and clinical solutions to help interventional cardiologists determine the most appropriate treatment for patients; the Peripheral Intervention BU, offering solutions for the treatment of patients with peripheral arterial disease; and the Critical Care Products BU.

The Group has operations worldwide and is headquartered in Singapore.

For more information, please visit www.biosensors.com.

Forward-Looking Statements

Certain statements herein include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of forward-looking terminology, such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “project” or “continue” or the negative thereof or other similar words. All forward looking statements involve risks and uncertainties, including, but not limited to, customer acceptance and market share gains, competition from companies that have greater financial resources; introduction of new products into the marketplace by competitors; successful product development; dependence on significant customers; the ability to recruit and retain quality employees as Biosensors grows; and economic and political conditions globally. Actual results may differ materially from those discussed in, or implied by, the forward-looking statements. The forward-looking statements speak only as of the date of this release and Biosensors assumes no duty to update them to reflect new, changing or unanticipated events or circumstances.